Published in Int J Radiat Oncol Biol Phys on November 01, 2008
Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis (2012) 1.10
Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol (2010) 1.01
MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS One (2013) 1.00
Sublethal total body irradiation leads to early cerebellar damage and oxidative stress. Curr Neurovasc Res (2010) 0.86
Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck (2012) 0.83
Genetic variations in VEGF and VEGFR2 and glioblastoma outcome. J Neurooncol (2010) 0.83
Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol (2013) 0.78
Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma. J Histochem Cytochem (2014) 0.76
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res (1995) 4.84
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res (1999) 4.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev (1998) 2.55
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol (1996) 2.42
Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer (1994) 2.24
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res (2006) 2.00
VEGF receptor signaling in tumor angiogenesis. Oncologist (2000) 1.94
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med (2005) 1.93
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A (2001) 1.90
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer (2000) 1.79
Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology (1999) 1.71
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res (2001) 1.59
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res (2004) 1.28
Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist (2007) 1.25
Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J (2002) 1.23
Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg (2003) 1.15
Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance? J Neurooncol (2005) 1.14
Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med (1999) 1.12
Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope (2001) 1.03
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res (2002) 1.00
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer (2002) 0.99
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2006) 0.96
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol (2007) 0.92
Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys (2005) 0.89
Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res (2002) 0.88
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys (2006) 0.88
A universal, multi-modality localization system for animal radiosurgery. Acta Neurochir Suppl (1994) 0.81
Targeted treatment: insights from studies of osteopontin and hypoxia. Lancet Oncol (2005) 0.79
Negligible radiation protection of endothelial cells by vascular endothelial growth factor. Oncol Rep (2007) 0.79
Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery. Exp Neurol (1998) 0.78
Progress and prospects in rat genetics: a community view. Nat Genet (2008) 6.01
Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology (2006) 2.04
On two-parameter models of photon cross sections: application to dual-energy CT imaging. Med Phys (2006) 1.10
DNA-PKcs regulates a single-stranded DNA endonuclease activity of Artemis. DNA Repair (Amst) (2010) 1.07
Cord-like mosaic patches in the adrenal cortex are fractal: implications for growth and development. FASEB J (2002) 0.98
Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res (2005) 0.97
Dose linearity and uniformity of a linear accelerator designed for implementation of multileaf collimation system-based intensity modulated radiation therapy. Med Phys (2003) 0.95
Quality assurance of immobilization and target localization systems for frameless stereotactic cranial and extracranial hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.91
Prostate motion and isocenter adjustment from ultrasound-based localization during delivery of radiation therapy. Int J Radiat Oncol Biol Phys (2005) 0.88
Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet (2003) 0.87
Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. Proteomics (2005) 0.84
Health-state utilities in a prisoner population: a cross-sectional survey. Health Qual Life Outcomes (2009) 0.83
Investigation of testosterone, androstenone, and estradiol metabolism in HepG2 cells and primary culture pig hepatocytes and their effects on 17βHSD7 gene expression. PLoS One (2012) 0.83
Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting. Peptides (2003) 0.82
Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides. Mol Cancer Ther (2004) 0.80
Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves. Bioconjug Chem (2003) 0.80
Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49. Biochem Biophys Res Commun (2005) 0.79
Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer. Clin Cancer Res (2007) 0.79
PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. Cancer Biol Ther (2007) 0.78
Enhanced long-term potentiation in the hippocampus of rats expressing mutant presenillin-1 is age related. Neurobiol Dis (2003) 0.78
A general approach for controlling transcription and probing epigenetic mechanisms: application to the CD4 locus. J Immunol (2013) 0.78
Estimation of internal organ motion-induced variance in radiation dose in non-gated radiotherapy. Phys Med Biol (2016) 0.77
Determination of xylazine and 2,6-xylidine in animal tissues by liquid chromatography-tandem mass spectrometry. J Food Sci (2013) 0.77
Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation. J Med Chem (2012) 0.77
Current successes and limitations of using genetic modification for blood pressure research. Pflugers Arch (2002) 0.76
Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med (2002) 0.76
Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer. Cancers (Basel) (2011) 0.76
Sequential effects of spadetail, one-eyed pinhead and no tail on midline convergence of nephric primordia during zebrafish embryogenesis. Dev Biol (2013) 0.76
Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation. J Med Chem (2009) 0.76
A simple method to extract DNA from hair shafts using enzymatic laundry powder. PLoS One (2013) 0.75
DNA uptake of 131I-iododeoxyuridine. J Nucl Med (2005) 0.75
Atypical teratoid rhabdoid tumor: long-term survival after chemoradiotherapy. Childs Nerv Syst (2015) 0.75
Availability of molecular imaging and "personalized medicine.". J Nucl Med (2009) 0.75
Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer. Prostate (2014) 0.75
Non-coplanar automatic beam orientation selection in cranial IMRT: a practical methodology. Phys Med Biol (2009) 0.75
Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma. J Pediatr Hematol Oncol (2017) 0.75
Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies. Prostate (2014) 0.75
On the verification of intransitive noninterference in mulitlevel security. IEEE Trans Syst Man Cybern B Cybern (2005) 0.75
Identification and quantitation of phenolic compounds from the seed and pomace of Perilla frutescens using HPLC/PDA and HPLC-ESI/QTOF/MS/MS. Phytochem Anal (2014) 0.75
Effects of field parameters on IMRT plan quality for gynecological cancer: a case study. J Appl Clin Med Phys (2005) 0.75
Radioiodinated agents for imaging multidrug resistant tumors. Med Chem (2009) 0.75